Skip to main content

Table 1 Patient characteristics at baseline

From: The relationship of weight change trajectory with medial temporal lobe atrophy in patients with mild Alzheimer’s disease: results from a cohort study

Age (year): n, median [25th -75th percentile]

214, 79 [75 - 82]

Women, n (%)

132 (61.7)

Social status

 

 alone, n (%)

93 (44.9)

 with partner, n (%)

108 (52.2)

 other*, n (%)

6 (2.9)

CIRS (score): n, median [25th -75th percentile]

214, 6.0 [4.0- 8.0]

Number of medications beside ChEI

 

 ≤4, n (%)

100 (46.9)

 >4 (polypharmacy), n (%)

113 (53.1)

Use of informal care, n (%)

182 (85.4)

Use of professional care, n (%)

99 (46.9)

MMSE (score): n, median [25th -75th percentile]

212, 23 [20 - 25]

 MMSE score ≤24, n (%)

138 (65.1)

 MMSE >26, n (%)

33 (15.6)

 Mild AD (MMSE 21 - 26), n (%)

126 (59.4)

 Moderate AD (MMSE 10 - 20), n (%)

53 (25.0)

 Moderate severe AD (MMSE 10 - 14), n (%)

3 (1.4)

 Severe AD (MMSE <10), n (%)

0 (0)

Clock-drawing test (score): n, median [25th -75th percentile]

193, 3.0 [2.0 - 4.5]

 Clock-drawing test score ≥3, n (%)

140 (72.5)

Presence of BPS, n (%)

51 (24.4)

ChEI which was started

 

 galantamine, n (%)

209 (97.7)

 rivastigmine, n (%)

5 (2.3)

Weight (kg): n, mean ± SD

214, 73.8 ± 12.0

BMI (weight/(height)2): n, median [25th -75th percentile]

203, 25.8 [23.5 - 28.6]

Use of ONS, n (%)

1 (0.5)

Appetite

 

 good, n (%)

170 (92.9)

 poor, n (%)

13 (7.1)

Self-reported weight loss, n (%)

28 (14.4)

Left MTA score

 

 0 (no atrophy), n (%)

1 (0.5)

 1 (mild atrophy), n (%)

15 (7.0)

 2 (moderate atrophy), n (%)

111 (51.9)

 3 (severe atrophy), n (%)

65 (30.4)

 4 (very severe atrophy), n (%)

22 (10.3)

Right MTA score

 

 0 (no atrophy), n (%)

2 (0.9)

 1 (mild atrophy), n (%)

15 (7.0)

 2 (moderate atrophy), n (%)

108 (50.5)

 3 (severe atrophy), n (%)

74 (34.6)

 4 (very severe atrophy), n (%)

15 (7.0)

  1. *Other, that is: with son or daughter, brother or sister. n, number of patients; CIRS, cumulative illness rating scale; ChEI, cholinesterase inhibitor; MMSE, mini mental state examination; AD, Alzheimer’s disease; BPS, behavioral and psychological symptoms; SD, standard deviation; BMI, body mass index; ONS, oral nutritional supplement; MTA, medial temporal lobe atrophy.